These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12591833)

  • 21. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.
    Heerey A; Suri S
    Pharmacoeconomics; 2005; 23(9):927-44. PubMed ID: 16153135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
    Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
    Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.
    Henriksson M; Epstein DM; Palmer SJ; Sculpher MJ; Clayton TC; Pocock SJ; Henderson RA; Buxton MJ; Fox KA
    Heart; 2008 Jun; 94(6):717-23. PubMed ID: 18032459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social].
    Arreola-Ornelas H; Rosado-Buzzo A; García-Mollinedo L; Dorantes Aguilar J; Muciño-Ortega E; Mould-Quevedo JF
    Cir Cir; 2012; 80(5):411-8. PubMed ID: 23351443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
    Wallentin L; Husted S; Kontny F; Swahn E
    Am J Cardiol; 1997 Sep; 80(5A):61E-63E. PubMed ID: 9296473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease. FRISC study group. Fragmin during Instability in Coronary Artery Disease.
    Sätre H; Holmvang L; Wagner GS; Lindahl B; Wallentin L
    Eur Heart J; 1999 May; 20(9):645-52. PubMed ID: 10208784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery.
    Rao C; Aziz O; Panesar SS; Jones C; Morris S; Darzi A; Athanasiou T
    BMJ; 2007 Mar; 334(7594):621. PubMed ID: 17337457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of tirofiban combined with dalteparin or unfractionated heparin in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction patients.
    Li WM; Yang XC; Wang LF; Ge YG; Wang HS; Xu L; Ni ZH; Zhang DP
    Chin Med J (Engl); 2011 Oct; 124(20):3275-80. PubMed ID: 22088520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deep venous thrombosis: a new task for primary health care. A randomised economic study of outpatient and inpatient treatment.
    Bäckman K; Carlsson P; Kentson M; Hansen S; Engquist L; Hallert C
    Scand J Prim Health Care; 2004 Mar; 22(1):44-9. PubMed ID: 15119520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
    Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
    Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study.
    Kontny F; Dale J; Abildgaard U; Pedersen TR
    J Am Coll Cardiol; 1997 Oct; 30(4):962-9. PubMed ID: 9316525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgical stabilisation of the spine compared with a programme of intensive rehabilitation for the management of patients with chronic low back pain: cost utility analysis based on a randomised controlled trial.
    Rivero-Arias O; Campbell H; Gray A; Fairbank J; Frost H; Wilson-MacDonald J
    BMJ; 2005 May; 330(7502):1239. PubMed ID: 15911536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction.
    Kakkar VV; Iyengar SS; De Lorenzo F; Hargreaves JR; Kadziola ZA;
    Indian Heart J; 2000; 52(5):533-9. PubMed ID: 11256775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
    Wallentin L; Lindhagen L; Ärnström E; Husted S; Janzon M; Johnsen SP; Kontny F; Kempf T; Levin LÅ; Lindahl B; Stridsberg M; Ståhle E; Venge P; Wollert KC; Swahn E; Lagerqvist B;
    Lancet; 2016 Oct; 388(10054):1903-1911. PubMed ID: 27585757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
    Dranitsaris G; Vincent M; Crowther M
    Pharmacoeconomics; 2006; 24(6):593-607. PubMed ID: 16761906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?
    Prescrire Int; 2000 Feb; 9(45):197-8. PubMed ID: 11503794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.
    Li A; Manohar PM; Garcia DA; Lyman GH; Steuten LM
    Thromb Res; 2019 Aug; 180():37-42. PubMed ID: 31200341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.